title: [Doubts as to the cardiovascular safety of rosiglitazone].
abstract: Recently, it was observed that rosiglitazone increased the risk of myocardial infarction. The American Food and Drug Administration therefore issued a safety alert. The practice guideline 'Diabetes mellitus type 2' of the Dutch College of General Practitioners only leaves room for the use of another thiazolidinedione, pioglitazone, and even that advice has been questioned. The new information on the serious adverse effects of rosiglitazone may further reduce the willingness to prescribe this drug for patients with type 2 diabetes.
authors.affiliation: Academisch Medisch Centrum/Universiteit van Amsterdam, Postbus 22.660, 1100 DD Amsterdam. j.b.hoekstra@amc.uva.nl
authors.forename: J B L
authors.initials: JB
authors.lastname: Hoekstra
authors.forename: P M M
authors.initials: PM
authors.lastname: Bossuyt
authors.forename: J H
authors.initials: JH
authors.lastname: de Vries
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced*; D000077154:Rosiglitazone; D012449:Safety; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone